United Therapeutics Corporation (NASDAQ:UTHR) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET

Company Participants

Dewey Steadman - Head-Investor Relations

Martine Rothblatt - Chairperson and Chief Executive Officer

Michael Benkowitz - President and Chief Operating Officer

James Edgemond - Chief Financial Officer and Treasurer

Leigh Peterson - Senior Vice President of Product Development

Pat Poisson - Executive Vice President of Technical Operations

Conference Call Participants

Jessica Fye - JPMorgan

Justin Phillips - Morgan Stanley

Hartaj Singh - Oppenheimer & Co.

Ashwani Verma - UBS

Joseph Thome - Cowen and Company

Andreas Argyrides - Wedbush Securities

Operator

Good morning and welcome to the United Therapeutics Corporation Fourth Quarter and Full Year 2022 Earnings Webcast. My name is Devin, and I will be your conference operator today. [Operator Instructions]

I will now turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics.

Dewey Steadman

Thanks, Devin, and good morning. It is my pleasure to welcome you to the United Therapeutics Corporation Fourth Quarter and Full Year 2022 Earnings Webcast. Accompanying on today's webcast are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; Pat Poisson, our Executive Vice President of Technical Operations; and Dr. Leigh Peterson, our Senior Vice President of Product Development.

Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update these forward-looking statements.

Today's remarks may also discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to service the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational use. Full prescribing information for the products are available on our website.

And United Therapeutics executives will participate in 3 investor conferences in March. First, Michael Benkowitz will participate in a fireside chat at the Cowen Healthcare Conference on Tuesday, March 7. Dr. Martine Rothblatt will participate in a fireside chat at the Oppenheimer Healthcare Conference on Monday, March 13, and our Chief Medical Officer, Gil Golden will participate in the JPMorgan Napa Valley Biotech Forum on Tuesday, March 21.